0001127602-24-014855.txt : 20240509 0001127602-24-014855.hdr.sgml : 20240509 20240509190531 ACCESSION NUMBER: 0001127602-24-014855 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240507 FILED AS OF DATE: 20240509 DATE AS OF CHANGE: 20240509 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Grygiel Nancy A. CENTRAL INDEX KEY: 0001816414 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37702 FILM NUMBER: 24932420 MAIL ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMGEN INC CENTRAL INDEX KEY: 0000318154 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 953540776 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 BUSINESS PHONE: (805)447-1000 MAIL ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 FORMER COMPANY: FORMER CONFORMED NAME: AMGEN DATE OF NAME CHANGE: 19870305 4 1 form4.xml PRIMARY DOCUMENT X0508 4 2024-05-07 0000318154 AMGEN INC AMGN 0001816414 Grygiel Nancy A. ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320 1 SVP & CCO 0 Common Stock 2024-05-07 4 A 0 499 0 A 10300 D Common Stock 99.9653 I 401(k) Plan Nqso (Right to Buy) 300.30 2024-05-07 4 A 0 3244 300.30 A 2026-05-07 2034-05-07 Common Stock 3244 3244 D The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/7/2026, 5/7/2027 and 5/7/2028, respectively. These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 2,780 RSUs which will vest on 7/31/2024; 199 RSUs which will vest on 4/30/2025; 435 RSUs which will vest in installments of 214 on 5/2/2025, and one installment of 221 on 5/2/2026; 635 RSUs which will vest in installments of 209 on 5/2/2025, 210 on 5/2/2026 and 216 on 5/2/2027; and 499 RSUs which will vest in installments of 164 on 5/7/2026, 165 on 5/7/2027, and 170 on 5/7/2028. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. These shares include 424 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. These are shares acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing. These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/7/2026, 5/7/2027 and 5/7/2028, respectively. /s/ Nancy A. Grygiel 2024-05-08